Close menu




August 2nd, 2022 | 10:57 CEST

These sources of return concern us all: Fresenius, Defence Therapeutics, BioNTech

  • Biotechnology
Photo credits: pixabay.com

When people receive an unexpected diagnosis or a loved one suddenly dies, our health suddenly becomes very important. Even though there is often no room for such topics in the daily lives of investors, it is worthwhile to deal with health for several reasons. On the one hand, preventive care brings the most important of all returns; on the other hand, this rather unpleasant topic in everyday life also holds opportunities if we focus on health risks and look at possible solutions. We present three stocks from the healthcare sector that deserve attention.

time to read: 3 minutes | Author: Nico Popp
ISIN: FRESENIUS SE+CO.KGAA O.N. | DE0005785604 , DEFENCE THERAPEUTICS INC | CA24463V1013 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Fresenius: What is going on?

    The current share price of dialysis specialist Fresenius is a tragedy: In the past ten years, the share price has not been as low as it is today. If a stock split is also considered, the share is valued much lower today than it was back then. The weaker result at the beginning of the year was due to burdens in the wake of the pandemic. Fresenius is currently doing particularly well with the Helios hospital chain, which has significantly increased its sales in recent months. Investors in Fresenius always benefit indirectly from the business of its subsidiary Fresenius Medical Care - here, sales rose by 8% at the beginning of the year. But why is the Fresenius share not getting off the ground?

    The debt ratio at Fresenius is currently around 60% - and rising. In times of rising interest rates, investors are therefore becoming cautious. Although the Company wants to become significantly more profitable by the end of next year and save around EUR 150 million annually, this information has been known on the market for some time now, without investors having bought into it when the share price was falling. With another pandemic fall looming, Fresenius' "covid-sensitive" stock does not appear to be a good choice. However, the stable dividend, which currently offers a yield of more than 3%, is a positive factor.

    Defence Therapeutics: Renowned institutes pave the way for approval procedures starting in 2023

    Defence Therapeutics does not pay a dividend. However, a payout is the last thing investors expect from the Canadian biotech company. Defence Therapeutics has several mainstays and works, among other things, on vaccines against cancer, such as skin or breast cancer. The Company's own patented drug enhancer Accum™ has potential as an active ingredient in addition to its intrinsic property, as it is highly toxic and is said to offer potential in tumors when applied in a targeted manner. A few weeks ago, the Company announced plans to further research the technology in collaboration with internationally renowned institutes such as the Curie Institute, the Institut de Recherche en Cancérologie de Montpellier and the HUS Comprehensive Cancer Center from Finland. These collaborations with different foci and experts could yield important insights for Defence.

    In early 2023, Defence Therapeutics plans to launch as many as three Phase 1 trials to drive regulatory approval of its technology. "Defence's Accum™ platform was primarily developed and tested in vitro and in vivo to improve intranuclear drug delivery for several FDA-approved antibody conjugates or novel conjugates in development. We strongly believe that all these important results achieved this year related to Accum™ ADCs will further demonstrate the efficacy of our Accum™ technology and take Defence to a new level," said Sebastien Plouffe, CEO of Defence Therapeutics. After falling significantly in recent weeks, the stock could become interesting again as we head into winter. In June, Canadian analyst firm Canaccord Genuity published detailed research on the Company. Defence Therapeutics should therefore be on several watch lists.

    BioNTech: Legal dispute leaves the market cold

    With fall approaching, BioNTech's stock is also worth a look. The Corona vaccine pioneer is currently working on improved versions of its vaccine for the fall. At the same time, the patent dispute with Tübingen-based rival CureVac entered a new round. BioNTech has defended itself in the US with a declaratory judgment action and assumes that it has not infringed any patents held by the Swabians. Even though legal disputes never go down well on the market, as a rule, the share has recently freed itself and is now at the upper end of the sideways trend that has been intact since the turn of the year. If new impulses follow, BioNTech can quickly head back toward EUR 200. However, investors should be aware that new highs are rather unlikely for BioNTech.


    If you consciously leave everyday life behind and focus on health risks, you will quickly realize how important innovative companies from the pharmaceutical and biotech sectors are. While the Fresenius share offers little perspective for the reasons mentioned, BioNTech appears to be on the rise despite being a dividend aristocrat. Defence Therapeutics could also offer great opportunities due to its low valuation and the numerous prospects surrounding its patented Accum™ technology.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Armin Schulz on March 28th, 2024 | 08:45 CET

    TUI, dynaCERT, Evotec - The profit is in buying

    • Hydrogen
    • greenhydrogen
    • travel
    • Biotechnology

    In the world of the financial markets, the timeless maxim applies: "The profit is in buying". This tried and tested stock market adage, which may seem trivial at first glance, is actually the key to financial success. Indeed, the price at which an investment is purchased often determines its subsequent triumph or failure long before the sale is even considered. Despite advances in technology and the complexity of markets, the basic lesson remains - buying wisely and at a well-considered price lays the foundation for profits. We have picked out three interesting candidates.

    Read

    Commented by Fabian Lorenz on March 26th, 2024 | 07:00 CET

    Out of BioNTech and into Defence Therapeutics and Evotec shares?

    • Biotechnology
    • Pharma

    The BioNTech share is currently out of steam. Although sentiment in the sector is improving, as star investor Cathie Wood recently invested in Moderna, the German biotech leader is not making any headway. The latest figures have not convinced analysts, and the price targets have even been further reduced. In contrast, the shares of Defence Therapeutics and Evotec appear to have more upside momentum. The Canadian cancer specialist has just raised new capital to develop its exciting pipeline. The Company has recently been granted a new US patent for its approach to cancer therapy. Evotec has a "Buy" recommendation. Could this mean the share is on the verge of an upward trend?

    Read

    Commented by André Will-Laudien on March 20th, 2024 | 07:30 CET

    Entry prices or Sell? BioNTech, Defence Therapeutics, Lufthansa and Nvidia in focus

    • Biotechnology
    • Pharma
    • chips
    • travel

    The stock market keeps running and running - but in reality, it is just a handful of stocks that make waves every day. Investors should now be vigilant because, like the recent correction in Bitcoin, the major indices could also fall by 10%. Of course, nobody is thinking about this at the moment; the mood is too good, almost euphoric, considering Germany's precarious economic situation. We analyze technical trends and fundamental assessments to ensure everything in your portfolio goes smoothly. In our view, BioNTech, Defence Therapeutics, and Lufthansa are on the runway, but when it comes to Nvidia, you should start deploying the parachute slowly. What is next here?

    Read